Acute lymphoblastic leukemia (ALL) affects both children and adults, but children have better chances to be cured, with long-term survival rates over 85% compared to 50-75% in adults. Scientists at St. Jude Children’s Research Hospital conducted a comprehensive study to understand the biological causes driving this difference. The work, published today in the Journal of Clinical Oncology, provides a blueprint for understanding B-cell acute lymphoblastic leukemia (B-ALL), the most common form of the disease.
Why patient centricity is the answer to the clinical trial enrolment gap – Pharmaceutical Technology
Share this article Credit: Shutterstock According to research published by The Economist Intelligence Unit[i], drugs developed using patient-centric designs have a higher chance of launch
February 13, 2024